Neolys Diagnostics was born from the outcome of the research by the Radiobiology Group on individual radiosensitivity. More than 15 years of work has been invested to set up a reliable method to assess radiosensitivity of healthy tissues and tumours. During this development, the researchers noticed not only the possibility to prevent side effects that some patients may endure when treated by radiotherapy, but also to predict the efficiency of radiation on the tumour. 

With this mission in mind, Nicolas Foray, Julien Gillet-Daubin and Gilles Devillers teamed up to fund Neolys Diagnostics. With a first test CE Marked, company’s goal today is to market and industrialize solutions to fit patient path and practitioner needs. 

As a result, radiation oncologists will be enabled to propose different predictive test specific to each patient, making the radiotherapeutical treatment individualized. This outcome of this project will help practitioners in a better decisionmaking process, and will improve the patients’ quality of life.

Last news

Radiosensitivity on a Blood test

Radiosensitivity on a Blood test  July 2017 After intense R&D, Neolys Diagnostics is proud to announce that our R...

BIO2017 – San Diego

BIO2017 – San Diego June 2017 Seeking for sound industrial partners at in North America and Asia, Neolys Diagnostics...

ESTRO 2017 - Vienna

ESTRO 2017 - Vienna May 2017 During the ESTRO (European Society for Radiotherapy and Oncology) Congress in Vienna, Dr ...

All news

Our Technology

Our technology is the result of over ten years of research by the Radiobiology Group. Their work on individual sensitivity have allowed to set up predictive tests. This technology offers a promissing solution, optimizing the efficiency of radiotherapy treatments and preventing toxicity at the same time.

Read more +